MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1504)	7/15/2004 1:04:48 PM
From: Icebrg	Read Replies (1) of 1826

MGI Pharma "outperform," estimates raised Thursday, July 15, 2004 9:14:08 AM ET Robert W. Baird NEW YORK, July 15 (New Ratings) – Analysts at Robert W Baird reiterate their "outperform" rating on MGI Pharma Inc (MOGN.NAS), while raising their estimates for the company. The target price is set to $35. In a research note published this morning, the analysts mention that MGI Pharma reported higher-than-expected sales of its Aloxi drug during 2Q04. Robert W Baird expresses its optimism regarding the company’s co-promotion agreement with Alpharma. The deal would support immediate leverage for MGI Pharma’s oncology sales force, the analysts believe. The EPS estimate for 2004 has been raised from $0.26 to $0.48.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next